全文获取类型
收费全文 | 18822篇 |
免费 | 1355篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 149篇 |
儿科学 | 726篇 |
妇产科学 | 581篇 |
基础医学 | 2323篇 |
口腔科学 | 289篇 |
临床医学 | 3014篇 |
内科学 | 3154篇 |
皮肤病学 | 218篇 |
神经病学 | 1595篇 |
特种医学 | 336篇 |
外国民族医学 | 1篇 |
外科学 | 1549篇 |
综合类 | 705篇 |
一般理论 | 40篇 |
预防医学 | 2816篇 |
眼科学 | 330篇 |
药学 | 1046篇 |
中国医学 | 9篇 |
肿瘤学 | 1329篇 |
出版年
2023年 | 100篇 |
2022年 | 147篇 |
2021年 | 350篇 |
2020年 | 218篇 |
2019年 | 359篇 |
2018年 | 376篇 |
2017年 | 283篇 |
2016年 | 354篇 |
2015年 | 421篇 |
2014年 | 542篇 |
2013年 | 845篇 |
2012年 | 1258篇 |
2011年 | 1331篇 |
2010年 | 656篇 |
2009年 | 613篇 |
2008年 | 1121篇 |
2007年 | 1245篇 |
2006年 | 1235篇 |
2005年 | 1232篇 |
2004年 | 1223篇 |
2003年 | 1176篇 |
2002年 | 1098篇 |
2001年 | 198篇 |
2000年 | 166篇 |
1999年 | 203篇 |
1998年 | 226篇 |
1997年 | 221篇 |
1996年 | 206篇 |
1995年 | 186篇 |
1994年 | 156篇 |
1993年 | 127篇 |
1992年 | 121篇 |
1991年 | 120篇 |
1990年 | 127篇 |
1989年 | 104篇 |
1988年 | 119篇 |
1987年 | 94篇 |
1986年 | 107篇 |
1985年 | 108篇 |
1984年 | 100篇 |
1983年 | 99篇 |
1982年 | 92篇 |
1981年 | 102篇 |
1980年 | 90篇 |
1979年 | 91篇 |
1978年 | 75篇 |
1977年 | 67篇 |
1976年 | 68篇 |
1974年 | 65篇 |
1972年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Christian Holm Hansen Shelley Lees Saidi Kapiga Janet Seeley Tony Barnett 《Global public health》2020,15(3):402-413
ABSTRACTMeasuring hope reliably and accurately remains an important research objective, not least in less prosperous settings where ‘holding on to hope’ may be critically important in the struggle against adverse life conditions. The State Hope Scale was designed for use in the US. Despite reported application in diverse cultures and using translations the scale has not been extensively validated outside US populations. This study contributes to a larger project exploring the measurement of hope and provides a critique of Snyder’s scale as used in a Tanzanian female population of 1021 urban microfinance participants. We evaluate the scale’s validity through assessment of the empirical distribution of scores, item response profiles, internal consistency and discriminatory ability. Participants mostly scored very high and many reached very near the maximum attainable score. Hardly any endorsed the negative half of the response scale. Several problems are discussed including poor discrimination and strong evidence of acquiescence response bias. We also found little association of the scale scores with hypothesised correlates of hope. Future improvements on the measurement of hope are recommended, especially in studies outside the narrow Western context in which the scale was devised. 相似文献
4.
ABSTRACTThis work collates data from the analysis of complex mixtures analysed in STRmix during routine no-suspect volume crime work. It interrogates the upload rate for these types of mixtures and which component of the profile has been able to be interpreted for upload. The number of profiles giving multiple uploads and the amount of replicate PCR analysis has been collated. 相似文献
5.
6.
A. Cattapan K. Browne D.M. Halperin A. Di Castri P. Fullsack J. Graham J.M. Langley B.A. Taylor S.A. McNeil S.A. Halperin 《Vaccine》2019,37(2):289-295
Introduction/Hypothesis
Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.Methods
An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.Results
A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.Conclusions/Recommendations
Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. 相似文献7.
8.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献9.
10.